Daewon Pharmaceutical Co., Ltd.

KOSE:A003220 Stock Report

Market Cap: ₩171.5b

Daewon Pharmaceutical Future Growth

Future criteria checks 3/6

Daewon Pharmaceutical is forecast to grow earnings and revenue by 69.8% and 6.6% per annum respectively. EPS is expected to grow by 69.9% per annum. Return on equity is forecast to be 11.3% in 3 years.

Key information

69.8%

Earnings growth rate

69.91%

EPS growth rate

Pharmaceuticals earnings growth23.1%
Revenue growth rate6.6%
Future return on equity11.26%
Analyst coverage

Low

Last updated19 May 2026

Recent future growth updates

Recent updates

Analysis Article • May 24

Daewon Pharmaceutical's (KRX:003220) Soft Earnings Don't Show The Whole Picture

The market for Daewon Pharmaceutical Co., Ltd.'s ( KRX:003220 ) shares didn't move much after it posted weak earnings...
Analysis Article • Jan 06

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) P/E Still Appears To Be Reasonable

With a price-to-earnings (or "P/E") ratio of 21x Daewon Pharmaceutical Co., Ltd. ( KRX:003220 ) may be sending very...
Analysis Article • Nov 22

Daewon Pharmaceutical's (KRX:003220) Conservative Accounting Might Explain Soft Earnings

Soft earnings didn't appear to concern Daewon Pharmaceutical Co., Ltd.'s ( KRX:003220 ) shareholders over the last...
Analysis Article • Aug 13

Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jul 17

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors

The Daewon Pharmaceutical Co., Ltd. ( KRX:003220 ) share price has done very well over the last month, posting an...
Analysis Article • Mar 21

There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings

The market for Daewon Pharmaceutical Co., Ltd.'s ( KRX:003220 ) shares didn't move much after it posted weak earnings...
Analysis Article • Mar 26

Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Mar 07

Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?

Dividend paying stocks like Daewon Pharmaceutical Co., Ltd. ( KRX:003220 ) tend to be popular with investors, and for...
Analysis Article • Feb 18

Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?

A look at the shareholders of Daewon Pharmaceutical Co., Ltd. ( KRX:003220 ) can tell us which group is most powerful...
Analysis Article • Jan 31

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

With its stock down 10% over the past month, it is easy to disregard Daewon Pharmaceutical (KRX:003220). However, the...
Analysis Article • Jan 13

Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
Analysis Article • Dec 24

Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend

It looks like Daewon Pharmaceutical Co., Ltd. ( KRX:003220 ) is about to go ex-dividend in the next 4 days. You can...
Analysis Article • Dec 10

Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article • Nov 22

Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?

Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) a good dividend stock? How can we tell? Dividend paying companies with...

Earnings and Revenue Growth Forecasts

KOSE:A003220 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028727,10049,70030,20053,2003
12/31/2027680,06738,30027,73349,8003
12/31/2026638,43317,90039,80039,8003
3/31/2026605,661-2,422-1,19643,950N/A
12/31/2025605,43542918242,313N/A
9/30/2025590,698-14,805-30342,854N/A
6/30/2025603,5899,41724,06480,092N/A
3/31/2025597,84711,269-12,48244,137N/A
12/31/2024598,16215,269-23,04730,035N/A
9/30/2024593,94516,019-23,10323,974N/A
6/30/2024566,09414,688-27,4393,232N/A
3/31/2024561,01023,72513,48935,232N/A
12/31/2023526,95223,91731,12451,734N/A
9/30/2023508,63426,1332,41117,105N/A
6/30/2023501,89931,74918,27330,359N/A
3/31/2023485,91731,07112,26727,176N/A
12/31/2022478,88531,94413,04826,413N/A
9/30/2022457,30834,72832,45247,937N/A
6/30/2022425,58829,92829,07043,137N/A
3/31/2022396,23925,57526,64537,726N/A
12/31/2021354,1766,98910,70722,413N/A
9/30/2021330,6863,431-1,0729,864N/A
6/30/2021315,870657-2,21910,266N/A
3/31/2021302,8892,120-5,1969,803N/A
12/31/2020308,50117,6409,56724,951N/A
9/30/2020318,29724,07317,18632,837N/A
6/30/2020318,09127,0379,73827,081N/A
3/31/2020322,12428,9043,49725,727N/A
12/31/2019317,82827,289N/A30,971N/A
9/30/2019310,80225,085N/A37,498N/A
6/30/2019299,87123,773N/A38,140N/A
3/31/2019291,78522,795N/A32,324N/A
12/31/2018286,65323,744N/A40,032N/A
9/30/2018279,33818,195N/A24,814N/A
6/30/2018279,93321,779N/A23,703N/A
3/31/2018273,78414,212N/A22,066N/A
12/31/2017265,46210,742N/A4,265N/A
9/30/2017258,27514,662N/A14,033N/A
6/30/2017248,35013,180N/A12,924N/A
3/31/2017245,49019,632N/A21,123N/A
12/31/2016240,72220,242N/A20,792N/A
9/30/2016235,04620,787N/A19,544N/A
6/30/2016229,69116,712N/A19,899N/A
3/31/2016222,26717,791N/A19,164N/A
12/31/2015216,18717,695N/A25,817N/A
9/30/2015208,27017,453N/A25,040N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A003220 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).

Earnings vs Market: A003220 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: A003220 is expected to become profitable in the next 3 years.

Revenue vs Market: A003220's revenue (6.6% per year) is forecast to grow slower than the KR market (17.5% per year).

High Growth Revenue: A003220's revenue (6.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A003220's Return on Equity is forecast to be low in 3 years time (11.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/02 11:46
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daewon Pharmaceutical Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jisoo LeeDAOL Investment & Securities Co., Ltd.
Jiwon LeeHeungkuk Securities Co., Ltd
Se Hoon SohnNH Investment & Securities Co., Ltd.